US Stocks Surge: Mannkind Biomedical Healthcare Rallies on September 30 Due to Rose Collaboration and Strong ReadyFlow Demand

Interpretation of the sharp rise of MannKind Biomedicine on September 30

Keywords: Rose partnership, ReadyFlow demand

1. On September 9, 2026, MannKind reached a global licensing and collaboration agreement with Rose Pharma to develop the inhaled short-acting GLP-1 drug ROSE-010 using Technosphere dry powder inhalation technology; the company will obtain Rose Pharma equity and potential sales royalties, as well as a seat on the board of directors.

2. On September 17, 2026, FUROSCIX ReadyFlow demonstrated early demand, with the number of coverage applications submitted by physicians reaching several times that of previous external infusion devices, and the demand expanded to new prescribing physicians in cardiology and nephrology; the company’s main business encompasses products for cardiometabolic and orphan pulmonary diseases.

(Disclaimer: This content has been summarized from publicly available information by AI technology and is for reference only. It does not constitute investment advice.)